Introduction
============

The Young Mania Rating Scale (YMRS) is a diagnostic questionnaire commonly used to evaluate manic symptoms in patients with bipolar 1 disorder and to assess treatment efficacy in clinical trials. This rating scale comprises eleven items (elevated mood, increased motor activity -- energy, sexual interest, sleep, irritability, speech -- rate and amount, language--thought disorder, content, disruptive--aggressive behavior, appearance, and insight). The total YMRS score is calculated as the summation of each of the eleven individual item scores.[@b1-ndt-9-409]

Asenapine is a tetracyclic antipsychotic with a unique pharmacologic profile indicated in several countries, including the United States and the European Union, for use in adult patients with manic episodes in bipolar I disorder. Acute efficacy was demonstrated in two 3-week trials in which asenapine monotherapy was significantly more effective than placebo at improving mania symptoms as assessed using the total YMRS score.[@b2-ndt-9-409],[@b3-ndt-9-409] The objective of this exploratory, post hoc analysis of the data pooled from the two positive trials was to identify the potential differential effects of asenapine or olanzapine on each of the eleven individual YMRS items, as indicators of the severity of specific bipolar mania symptom dimensions.

Materials and methods
=====================

Data were pooled from two 3-week randomized, placebo-and olanzapine-controlled, double-blind, double-dummy, multicenter, parallel-group trials (A7501004 and A7501005).[@b2-ndt-9-409],[@b3-ndt-9-409] Patients aged ≥ 18 years with a diagnosis of bipolar I disorder; current manic or mixed episodes according to the Mini International Neuropsychiatric Interview[@b4-ndt-9-409] and *Diagnostic and Statistical Manual of Mental Disorders, Fourth edition*, text revision criteria[@b5-ndt-9-409]; and a YMRS total score ≥ 20 at screening and baseline were eligible. Following a 7-day, single-blind placebo run-in phase, active treatment was initiated (day 1, n = 977) with asenapine 20 mg (10 mg twice daily \[BID\], morning and evening; n = 379), olanzapine 15 mg (once daily \[QD\]; n = 396), or placebo (n = 202). Thereafter, treatment continued with flexible dosing (asenapine at 10--20 mg daily \[5--10 mg BID\] and olanzapine at 5--20 mg QD). Patients remained in the research facility for ≥7 days of treatment and were discharged if clinically stable. A complete description of the design and eligibility criteria of both studies has been reported elsewhere.[@b2-ndt-9-409],[@b3-ndt-9-409]

Seven of the eleven individual YMRS items were scored on a 0 to 4 scale: appearance, insight, language--thought disorder, increased motor activity -- energy, elevated mood, sleep, and sexual interest. The remaining four items were scored on a 0 to 8 scale: disruptive--aggressive behavior, content, irritability, and speech -- rate and amount. The YMRS total score, with a range of 0 to 60, was a summation of each of the eleven individual scores, with the higher total YMRS scores refecting greater symptom severity. YMRS response rate was determined as the percentage of patients achieving ≥50% reduction from baseline in total YMRS score.

An exploratory post hoc analysis of the change from baseline in the eleven individual YMRS items was performed. An analysis of covariance model adjusted by baseline value was used to test for differences in changes from baseline in YMRS scores between groups. Last observations were carried forward (LOCF) for missing data. The results have not been corrected for multiplicity.

Results
=======

Patient characteristics
-----------------------

Pooled patient demographics and baseline characteristics are displayed in [Table 1](#t1-ndt-9-409){ref-type="table"}. Of the 977 treated patients, 680 (70%) completed the studies. The modified intent-to-treat population (treated patients with at least one post baseline YMRS assessment, n = 960) consisted of patients receiving asenapine 10 to 20 mg daily (n = 372), olanzapine 5 to 20 mg daily (n = 391), or placebo (n = 197).

YMRS item results
-----------------

Reductions from baseline to day 21 were significantly greater for asenapine and olanzapine compared with placebo for each of the eleven individual YMRS items ([Table 2](#t2-ndt-9-409){ref-type="table"}). Statistically significant reductions in YMRS total score were observed for both treatments compared with placebo, as reported previously.[@b2-ndt-9-409],[@b3-ndt-9-409]

In six of the YMRS items, statistically significant improvements from baseline were observed as early as Day 2 (mean change ± SD, LOCF) for asenapine (10--20 mg daily) and olanzapine (5--20 mg daily) compared with placebo: disruptive--aggressive behavior (−0.3 ± 1.15; −0.4 ± 1.14; −0.1 ± 1.16), content (−0.4 ± 1.22; −0.5 ± 1.48; −0.2 ± 0.90), irritability (−0.5 ± 1.41; −0.5 ± 1.33; −0.3 ± 1.15), elevated mood (−0.3 ± 0.75; −0.3 ± 0.73; −0.1 ± 0.63), sleep (−0.4 ± 0.88; −0.5 ± 0.92; −0.2 ± 0.74), and speech (−0.6 ± 1.23; −0.6 ± 1.27; −0.1 ± 0.96) (all comparisons *P* \< 0.05 for asenapine or olanzapine versus placebo).

No statistical difference was observed in the improvements seen with asenapine and olanzapine in the YMRS items of appearance, content, elevated mood, increased motor activity and insight. For the remaining items (language--thought disorder, sleep, sexual interest, disruptive--aggressive behavior, irritability, and speech) while both treatments were associated with significant improvement compared to placebo, olanzapine treatment was accompanied by a significantly greater improvement compared to asenapine (*P* \< 0.05 with no multiplicity adjustment).

YMRS response rate
------------------

Following treatment with asenapine or olanzapine a greater response rate (≥50% improvement in total YMRS score) was observed compared to placebo (42.5%, 52.4% and 29.4% respectively; *P* \< 0.05 for asenapine or olanzapine versus placebo).

Conclusion
==========

Reduction in manic symptoms over 21 days was associated with a broad-based improvement across all symptom domains, with no subset of symptoms predominating. For antipsychotics with sedative properties, such as asenapine or olanzapine, it might be suspected that efficacy in manic or mixed episodes would result mainly from effects limited to sleep disturbances and/or aggressive behavior. However, the post hoc analysis presented here suggests that manic and mixed symptom improvement with asenapine or olanzapine is broader and goes beyond effects of sedation, with the complete spectrum of YMRS items showing clinical benefit.

In the present analysis, a subset of YMRS items including disruptive--aggressive behavior, content, irritability, elevated mood, sleep, and speech showed significant differences in favor of asenapine or olanzapine, compared with placebo, as early as the second day of treatment. With both asenapine and olanzapine, improvement seen in the disruptive--aggressive behavior YMRS item was greater than the improvement observed with other YMRS items. Limitations of these analyses include that, as a post-hoc analysis, the hypotheses were not predefined and that the results were not corrected for multiplicity.

Clinicians can therefore expect clinically relevant benefits early in the course of treatment, at least in a subset of patients. In this context, it is worthwhile to mention that early improvement has been reported to be associated with an increased odds ratio of response or remission at the end of treatment.[@b6-ndt-9-409]
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###### 

Pooled demographic and baseline characteristics (intent-to-treat)

                         Placebo       Asenapine 10--20 mg daily   Olanzapine 5--20 mg daily
  ---------------------- ------------- --------------------------- ---------------------------
  Sex, N                 197           372                         391
   Female, n (%)         99 (50.3)     169 (45.4)                  161 (41.2)
   Male, n (%)           98 (49.7)     203 (54.6)                  230 (58.8)
  Race, N                197           372                         391
   Asian, n (%)          41 (20.8)     75 (20.2)                   78 (19.9)
   Black, n (%)          34 (17.3)     67 (18.0)                   71 (18.2)
   White, n (%)          110 (55.8)    221 (59.4)                  221 (56.5)
   Other, n (%)          12 (6.1)      9 (2.4)                     21 (5.4)
  Age group              197           372                         391
   18--64 years, n (%)   193 (98)      365 (98.1)                  386 (98.7)
   ≥65 years, n (%)      4 (2)         7 (1.9)                     5 (1.3)
  Age, N                 197           372                         391
   Years, mean (SD)      38.7 (12.2)   38.8 (12.1)                 39.2 (11.1)
  Current episode, N     197           372                         391
   Manic, n (%)          131 (66.5)    265 (71.2)                  269 (68.8)
   Mixed, n (%)          66 (33.5)     107 (28.8)                  122 (31.2)
  Weight, N              197           372                         391
   Kg, mean (SD)         78 (19.5)     76.9 (19.3)                 78.9 (19.9)
  BMI, N                 196           371                         389
   Kg/m^2^, mean (SD)    27.3 (6.1)    26.5 (5.5)                  27.2 (5.9)

**Abbreviations:** BMI, body mass index; SD, standard deviation.

###### 

Change in Young Mania Rating Scale (YMRS) score at day 21 (last observation carried forward, intent-to-treat)

                                              Placebo N = 197   Asenapine 10--20 mg daily N = 372   Olanzapine 5--20 mg daily N = 391
  ------------------------------------------- ----------------- ----------------------------------- -----------------------------------
  Day 21, n                                   197               372                                 391
  Total YMRS score (0--60)                                                                          
   Baseline mean (SD)                         28.7 (6.2)        28.8 (6.2)                          29.2 (6.3)
   LS mean change (SE)                        −6.7 (0.75)       −11.2 (0.54)                        −13.6 (0.53)
   *P*-value (versus placebo)                                   \<0.0001                            \<0.0001
   *P*-value (versus olanzapine)                                0.0013                              
  Appearance (0--4)                                                                                 
   Baseline mean (SD)                         1.2 (0.80)        1.2 (0.86)                          1.3 (0.94)
   LS mean change (SE)                        −0.3 (0.06)       −0.5 (0.04)                         −0.6 (0.04)
   *P*-value (versus placebo)                                   0.0042                              \<0.0001
   *P*-value (versus olanzapine)                                0.0518                              
  Insight (0--4)                                                                                    
   Baseline mean (SD)                         1.0 (1.26)        1.1 (1.38)                          1.1 (1.36)
   LS mean change (SE)                        −0.2 (0.06)       −0.4 (0.04)                         −0.5 (0.04)
   *P*-value (versus placebo)                                   0.0035                              \<0.0001
   *P*-value (versus olanzapine)                                0.115                               
  Language--thought disorder (0--4)                                                                 
   Baseline mean (SD)                         2.1 (0.63)        2.1 (0.66)                          2.1 (0.70)
   LS mean change (SE)                        −0.5 (0.06)       −0.8 (0.05)                         −1.0 (0.05)
   *P*-value (versus placebo)                                   0.0008                              \<0.0001
   *P*-value (versus olanzapine)                                0.0078                              
  Increased motor activity -- energy (0--4)                                                         
   Baseline mean (SD)                         2.8 (0.69)        2.8 (0.71)                          2.8 (0.66)
   LS mean change (SE)                        −0.8 (0.09)       −1.1 (0.06)                         −1.2 (0.06)
   *P*-value (versus placebo)                                   0.0023                              \<0.0001
   *P*-value (versus olanzapine)                                0.12                                
  Elevated mood (0--4)                                                                              
   Baseline mean (SD)                         2.6 (0.88)        2.7 (0.86)                          2.6 (0.85)
   LS mean change (SE)                        −0.6 (0.08)       −1.0 (0.06)                         −1.1 (0.05)
   *P*-value (versus placebo)                                   0.0002                              \<0.0001
   *P*-value (versus olanzapine)                                0.2696                              
  Sleep (0--4)                                                                                      
   Baseline mean (SD)                         2.3 (0.84)        2.2 (0.92)                          2.2 (0.92)
   LS mean change (SE)                        −0.6 (0.08)       −1.0 (0.06)                         −1.2 (0.06)
   *P*-value (versus placebo)                                   \<0.0001                            \<0.0001
   *P*-value (versus olanzapine)                                0.0067                              
  Sexual interest (0--4)                                                                            
   Baseline mean (SD)                         1.5 (1.16)        1.5 (1.11)                          1.6 (1.16)
   LS mean change (SE)                        −0.4 (0.07)       −0.6 (0.05)                         −0.8 (0.05)
   *P*-value (versus placebo)                                   0.0101                              \<0.0001
   *P*-value (versus olanzapine)                                0.0178                              
  Disruptive--aggressive behavior (0--8)                                                            
   Baseline mean (SD)                         2.9 (1.65)        2.8 (1.60)                          2.9 (1.59)
   LS mean change (SE)                        −0.3 (0.13)       −1.0 (0.09)                         −1.3 (0.09)
   *P*-value (versus placebo)                                   \<0.0001                            \<0.0001
   *P*-value (versus olanzapine)                                0.0134                              
  Content (0--8)                                                                                    
   Baseline mean (SD)                         4.2 (2.17)        4.3 (2.10)                          4.3 (2.14)
   LS mean change (SE)                        −0.9 (0.15)       −1.7 (0.11)                         −1.9 (0.11)
   *P*-value (versus placebo)                                   \<0.0001                            \<0.0001
   *P*-value (versus olanzapine)                                0.1517                              
  Irritability (0--8)                                                                               
   Baseline mean (SD)                         3.9 (1.39)        3.7 (1.51)                          4.0 (1.40)
   LS mean change (SE)                        −0.8 (0.13)       −1.3 (0.10)                         −1.7 (0.09)
   *P*-value (versus placebo)                                   0.0008                              \<0.0001
   *P*-value (versus olanzapine)                                0.0127                              
  Speech -- rate and amount (0--8)                                                                  
   Baseline mean (SD)                         4.2 (1.53)        4.3 (1.55)                          4.3 (1.67)
   LS mean change (SE)                        −1.2 (0.14)       −1.8 (0.10)                         −2.1 (0.10)
   *P*-value (versus placebo)                                   0.0007                              \<0.0001
   *P*-value (versus olanzapine)                                0.028                               

**Abbreviations:** LS, least squares; SD, standard deviation; SE, standard error.
